- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Sciclone Pharmaceuticals Inc
+ Add to WatchlistSCLN:US
4.9700 USD 0.2000 4.19%As of 20:10:00 ET on 05/23/2013.
Snapshot for Sciclone Pharmaceuticals Inc (SCLN)
| Open: | 4.7500 | Day's Range: | 4.7000 - 4.9800 | Volume: | 183,422 |
|---|---|---|---|---|---|
| Previous Close: | 4.9700 | 52wk Range: | 3.6800 - 7.5800 | 1-Yr Rtn: | -15.48% |
Key Statistics for SCLN
| Current P/E Ratio (ttm) | 10.3542 |
|---|---|
| Estimated P/E(12/2013) | 8.2833 |
| Relative P/E vs. SPX | 0.6427 |
| Earnings Per Share (USD) (ttm) | 0.4800 |
| Est. EPS (USD) (12/2013) | 0.6000 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 268.77 |
| Shares Outstanding (M) | 54.08 |
| 30 Day Average Volume | 244,342 |
| Price/Book (mrq) | 1.8933 |
| Price/Sale (ttm) | 1.8019 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 06/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for SCLN
Company Profile & Key Executives for SCLN
SciClone Pharmaceuticals, Inc. is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs. The Company's products are for treating chronic and life-threatening diseases such as cancer, hepatitis B, hepatitis C, cystic fibrosis, and immune system disorders.
| Friedhelm BlobelPresident/CEO | Hong ZhaoCEO:China Operations |
| Gary S TitusSenior VP:Finance/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
SCLN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page